1.80
-0.03 (-1.64%)
| Previous Close | 1.83 |
| Open | 1.86 |
| Volume | 189,846 |
| Avg. Volume (3M) | 1,352,422 |
| Market Cap | 113,865,352 |
| Price / Sales | 1.12 |
| Price / Book | 2.11 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Profit Margin | -36.23% |
| Operating Margin (TTM) | -323.11% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | 44.90% |
| Quarterly Earnings Growth (YOY) | 220.80% |
| Total Debt/Equity (MRQ) | 47.35% |
| Current Ratio (MRQ) | 3.28 |
| Operating Cash Flow (TTM) | -69.62 M |
| Levered Free Cash Flow (TTM) | -40.45 M |
| Return on Assets (TTM) | -26.29% |
| Return on Equity (TTM) | -60.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | MacroGenics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.01% |
| % Held by Institutions | 73.84% |
| 52 Weeks Range | ||
| Median | 4.00 (122.22%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 10 Mar 2026 | 4.00 (122.22%) | Buy | 2.36 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |